Revenue: As of FY2026 Q1, the actual value is USD 31.27 M.

EPS: As of FY2026 Q1, the actual value is USD -0.01.

EBIT: As of FY2026 Q1, the actual value is USD 1.048 M.

Financial Performance Overview

CareCloud, Inc. reported a net revenue of $31,270 thousand for the three months ended March 31, 2026, marking a 13% increase compared to $27,632 thousand in the prior year period .

Segment Revenue

• Healthcare IT: Revenue for this segment was $27,504 thousand in Q1 2026, an increase from $24,643 thousand in Q1 2025 . This segment’s technology-enabled business solutions accounted for approximately 74% of total revenue in Q1 2026, compared to 64% in Q1 2025 . Other healthcare IT services contributed approximately 14% of revenue in Q1 2026 and 25% in Q1 2025 .
• Medical Practice Management: This segment generated $3,766 thousand in Q1 2026, an increase from $2,989 thousand in Q1 2025 . This segment accounted for approximately 12% of total revenue in Q1 2026 and 11% in Q1 2025 .

Operational Metrics

• Net Income: Net income was $922 thousand in Q1 2026, a decrease from $1,948 thousand in Q1 2025 .
• Operating Income: Operating income was $1,000 thousand in Q1 2026, down from $2,019 thousand in Q1 2025 . The GAAP operating margin decreased to 3.2% in Q1 2026 from 7.3% in Q1 2025 .
• Total Operating Expenses: Total operating expenses increased by 18% to $30,270 thousand in Q1 2026 from $25,613 thousand in Q1 2025 .
  • Direct Operating Costs: These costs increased by 9% to $16,850 thousand in Q1 2026 from $15,464 thousand in Q1 2025 . As a percentage of revenue, direct operating costs were 53.9% in Q1 2026, down from 56.0% in Q1 2025 .
  • Selling and Marketing Expense: This expense grew by 25% to $1,414 thousand in Q1 2026 from $1,131 thousand in Q1 2025 .
  • General and Administrative Expense: This increased by 27% to $5,496 thousand in Q1 2026 from $4,332 thousand in Q1 2025 .
  • Research and Development Expense: This expense saw a 96% increase to $2,416 thousand in Q1 2026 from $1,235 thousand in Q1 2025 .
  • Depreciation and Amortization: These combined expenses rose to $4,037 thousand in Q1 2026 from $3,337 thousand in Q1 2025 .
• Adjusted EBITDA: Adjusted EBITDA was $5,370 thousand in Q1 2026, compared to $5,595 thousand in Q1 2025 .
• Non-GAAP Adjusted Operating Income: This metric was $2,207 thousand in Q1 2026, with an adjusted operating margin of 7.1%, compared to $2,342 thousand and 8.5% in Q1 2025 .
• Net Loss Attributable to Common Shareholders: The net loss attributable to common shareholders was - $443 thousand in Q1 2026, an improvement from - $863 thousand in Q1 2025 .

Cash Flow

• Net Cash Provided by Operating Activities: This decreased to $3,611 thousand in Q1 2026 from $5,113 thousand in Q1 2025 .
• Net Cash Used in Investing Activities: This was - $1,232 thousand in Q1 2026, compared to - $1,510 thousand in Q1 2025 . Capital expenditures were $412 thousand in Q1 2026 and $624 thousand in Q1 2025 . Software development costs capitalized were $820 thousand in Q1 2026 and $846 thousand in Q1 2025 .
• Net Cash Used in Financing Activities: This was - $2,150 thousand in Q1 2026, including $1,916 thousand in preferred stock dividends paid, - $177 thousand in debt repayments, and - $57 thousand for contingent consideration payments . In Q1 2025, it was - $1,932 thousand, including $1,730 thousand in preferred stock dividends paid and - $181 thousand in debt repayments .

Unique Metrics

• Providers and Practices Served: As of March 31, 2026, the company provided services to approximately 45,000 providers, representing about 2,900 independent medical practices, hospitals, and service organizations, compared to 40,000 providers in the prior year .
• Acquisition Revenue: Revenue from the Medsphere acquisition was approximately $6.8 million during Q1 2026 . Revenue from MAP App clients was approximately $191 thousand, and from RevNu clients was approximately $300 thousand during Q1 2026 .

Future Outlook and Strategy

Management is focused on enhancing liquidity and financial position by managing expenses and growing revenue, with forecasts indicating sufficient liquidity for the next twelve months . The company plans to fully redeem the outstanding Series B Preferred Stock in May 2026, utilizing approximately $41.6 million from a new $50 million joint credit facility . Additionally, an At The Market Offering Agreement allows for the sale of common stock up to $60 million for general corporate purposes, including potential acquisitions, debt repayment, capital expenditures, and preferred stock redemption .